Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment

Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders include increased flux of free fatty acids (FFA), raised triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C)...

Descripción completa

Detalles Bibliográficos
Autores principales: Athyros, Vasilios G, Tziomalos, Konstantinos, Karagiannis, Asterios, Mikhailidis, Dimitri P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109607/
https://www.ncbi.nlm.nih.gov/pubmed/21660248
http://dx.doi.org/10.2174/1874192401105010024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109607/
https://www.ncbi.nlm.nih.gov/pubmed/21660248
http://dx.doi.org/10.2174/1874192401105010024

Ejemplares similares